Copyright © 2005, European Society of Cardiology
The role of natriuretic peptides in cardioprotection
aDepartment of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi, 321-0293 Japan
bDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7525
* Corresponding author. Tel.: +81 282 86 1111; fax: +81 282 86 1596. Email address: nishikim{at}dokkyomed.ac.jp
Atrial natriuretic peptide (ANP) and brain (B-type) natriuretic peptide (BNP) are circulating hormones of cardiac origin that play an important role in the regulation of intravascular blood volume and vascular tone. The plasma concentrations of ANP and BNP are elevated in heart failure, and they are considered to compensate for heart failure because of their diuretic, natriuretic, and vasodilating actions and inhibitory effects on renin and aldosterone secretion. Evidence is also accumulating from recent work that ANP and BNP exert their cardioprotective functions not only as circulating hormones but also as local autocrine and/or paracrine factors. In studies using cultured neonatal myocytes and fibroblasts, exogenous administration of both ANP and ANP antagonists demonstrated that ANP has antihypertrophic and antifibrotic functions. Corroborating these in vitro results, mice lacking natriuretic receptor-A (NPR-A), the receptor for ANP and BNP, develop cardiac hypertrophy and fibrosis independent of their blood pressure. Recent studies also suggest that the intracardiac natriuretic peptides/cGMP system plays a counter-regulatory role against the intracardiac renin–angiotensin–aldosterone system and TGF-beta mediated pathway. In a clinical setting, human recombinant ANP and BNP may be used for a therapy of heart failure; however, further evaluation is required in the future.
KEYWORDS Atrial natriuretic peptide; Brain natriuretic peptide; C-type natriuretic peptide; Cyclic guanosine monophosphate; Hypertrophy; Heart failure; Fibroblast; Fibrosis; Cardioprotective
Time for primary review 19 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B.-Y. Kang and J. L. Mehta Rosuvastatin Attenuates Ang II--Mediated Cardiomyocyte Hypertrophy via Inhibition of LOX-1 Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2009; 14(4): 283 - 291. [Abstract] [PDF]
|
|
|
|
 |
|
 J. L. Sartoretto, B. Y. Jin, M. Bauer, F. B. Gertler, R. Liao, and T. Michel Regulation of VASP phosphorylation in cardiac myocytes: differential regulation by cyclic nucleotides and modulation of protein expression in diabetic and hypertrophic heart Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1697 - H1710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Glenn, D. Rahmutula, M. Nishimoto, F. Liang, and D. G. Gardner Atrial natriuretic peptide suppresses endothelin gene expression and proliferation in cardiac fibroblasts through a GATA4-dependent mechanism Cardiovasc Res, November 1, 2009; 84(2): 209 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jankowski GATA4, a new regulator of cardiac fibroblasts, is sensitive to natriuretic peptides Cardiovasc Res, November 1, 2009; 84(2): 176 - 177. [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Johnson and K. R. Olson Responses of the trout cardiac natriuretic peptide system to manipulation of salt and water balance Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1170 - R1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kasama, M. Furuya, T. Toyama, S. Ichikawa, and M. Kurabayashi Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction Eur. Heart J., June 2, 2008; 29(12): 1485 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Koitabashi, M. Arai, K. Niwano, A. Watanabe, M. Endoh, M. Suguta, T. Yokoyama, H. Tada, T. Toyama, H. Adachi, et al. Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure Eur J Heart Fail, April 1, 2008; 10(4): 373 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Degousee, S. Fazel, D. Angoulvant, E. Stefanski, S.-C. Pawelzik, M. Korotkova, S. Arab, P. Liu, T. F. Lindsay, S. Zhuo, et al. Microsomal Prostaglandin E2 Synthase-1 Deletion Leads to Adverse Left Ventricular Remodeling After Myocardial Infarction Circulation, April 1, 2008; 117(13): 1701 - 1710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Murray, J. D. Gardner, S. P. Levick, G. L. Brower, L. G. Morgan, and J. S. Janicki Response of cardiac mast cells to atrial natriuretic peptide Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1216 - H1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gutkowska, A. Paquette, D. Wang, J.-M. Lavoie, and M. Jankowski Effect of exercise training on cardiac oxytocin and natriuretic peptide systems in ovariectomized rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R267 - R275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Martinson, M. P. Hans, G.-D. David, and A. M. Elizabeth Readers' choice: Hot papers downloaded in 2006 Cardiovasc Res, March 1, 2007; 73(4): 619 - 622. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Li, S. Oparil, L. Novak, X. Cao, W. Shi, J. Lucas, and Y.-F. Chen ANP signaling inhibits TGF-beta-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells J Appl Physiol, January 1, 2007; 102(1): 390 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-J. Du, X.-M. Gao, H. Kiriazis, X.-L. Moore, Z. Ming, Y. Su, A. M. Finch, R. A. Hannan, A. M. Dart, and R. M. Graham Transgenic {alpha}1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival Cardiovasc Res, September 1, 2006; 71(4): 735 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Wilhide and W. K. Jones Potential Therapeutic Gene for the Treatment of Ischemic Disease: Ad2/Hypoxia-Inducible Factor-1{alpha} (HIF-1)/VP16 Enhances B-Type Natriuretic Peptide Gene Expression via a HIF-1-Responsive Element Mol. Pharmacol., June 1, 2006; 69(6): 1773 - 1778. [Abstract] [Full Text] [PDF]
|
|